Business Segments Charles River Laboratories International, Inc. Berne S.E.
Stocks
RV6
US1598641074
Biotechnology & Medical Research
|
End-of-day quote
Berne S.E.
2026-09-03
|
5-day change | 1st Jan Change | ||
| 233.98 CHF | +0.82% |
|
-3.43% | - |
| Aug. 20 | Charles River Laboratories International Insider Sold Shares Worth $599,711, According to a Recent SEC Filing | MT |
| Aug. 20 | Charles River, Medigen Partner on Multivalent Enterovirus Vaccine | MT |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Operating Income: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Life Sciences Tools and Services | ||||||||||
Discovery and Safety Assessment (DSA) | 2.11B | 2.45B | 2.62B | 2.45B | 2.4B | |||||
CAPEX | -101M | -190M | -205M | -128M | -133M | |||||
D&A | 177M | 179M | 175M | 191M | 174M | |||||
Operating Income | 407M | 533M | 606M | 443M | 425M | |||||
Research Models and Services (RMS) | 690M | 739M | 792M | 829M | 846M | |||||
CAPEX | -61.19M | -44.14M | -52.82M | -64.13M | -38.84M | |||||
D&A | 39.12M | 49.27M | 55.57M | 73.81M | 81.08M | |||||
Operating Income | 167M | 160M | 155M | 114M | 44.57M | |||||
| - | - | - | - | 2.4B | ||||||
| - | - | - | - | 846M | ||||||
Pharmaceutical Contract Research Organization | ||||||||||
Manufacturing Solutions (Manufacturing) | 742M | 790M | 721M | 769M | 766M | |||||
CAPEX | -58.88M | -87.08M | -58.13M | -38.5M | -41.43M | |||||
D&A | 46.2M | 72.95M | 79.98M | 89.96M | 140M | |||||
Operating Income | 246M | 167M | 88.33M | -71.45M | -184M | |||||
| - | - | - | - | 766M | ||||||
D&A | 2.97M | 2.18M | 3.85M | 6.84M | 7.99M | |||||
Operating Income | - | -209M | -232M | -258M | -260M | |||||
Operating Income | -17.68M | - | - | - | - | |||||
CAPEX | -7.23M | -3.95M | -2.68M | -1.98M | -5.93M | |||||
Operating Income | -2.97M | - | - | - | - | |||||
Operating Income | -18.45M | - | - | - | - | |||||
Operating Income | -25.37M | - | - | - | - | |||||
Operating Income | -92.46M | - | - | - | - | |||||
Operating Income | -43.02M | - | - | - | - |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
United States (U.S) | 1.93B | 2.34B | 2.35B | 2.24B | 2.14B | |||||
Total Assets | 755M | 896M | 964M | 942M | 919M | |||||
| - | - | - | - | 501M | ||||||
Europe | 1.04B | 1.03B | 1.08B | 1.08B | 1.1B | |||||
Total Assets | 323M | 349M | 407M | 413M | 469M | |||||
Canada | 339M | 399M | 487M | 482M | 501M | |||||
Total Assets | 145M | 135M | 157M | 147M | 163M | |||||
| - | - | - | - | 64.86M | ||||||
Asia Pacific | 223M | 193M | 201M | 197M | 205M | |||||
Total Assets | 64.86M | 82.78M | 74.6M | 66.05M | 61.81M | |||||
Other | 7.29M | 9.96M | 16.85M | 52.82M | 64.86M | |||||
Total Assets | 2.12M | 1.98M | 36.1M | 36.34M | 42.19M | |||||
| - | - | - | - | 205M | ||||||
Japan | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
| - | - | - | - | 2.14B | ||||||
| - | - | - | - | 1.1B |
Select your edition
All financial news and data tailored to specific country editions
